Institutional Repository UDD

Daptomycin for the treatment of bacteraemia due to vancomycin-resistant enterococci

Show simple item record

dc.contributor.author Munita, Jose
dc.contributor.author Murray, Barbara
dc.contributor.author Arias, Cesar
dc.date.accessioned 2017-04-05T14:46:19Z
dc.date.available 2017-04-05T14:46:19Z
dc.date.issued 2014
dc.identifier.citation Int J Antimicrob Agents. 2014 Nov;44(5):387-395 es_CL
dc.identifier.uri http://dx.doi.org/10.1016/j.ijantimicag.2014.08.002 es_CL
dc.identifier.uri http://hdl.handle.net/11447/1090
dc.description.abstract Treatment of severe infections caused by vancomycin-resistant enterococci (VRE) is challenging due to the scarcity of reliable therapeutic alternatives. In this context, daptomycin (DAP), a lipopeptide antibiotic, has emerged as an interesting alternative as it is one of the few compounds that retain in vitro bactericidal activity against VRE isolates, although it has not been approved for this purpose by regulatory agencies. In this review, we will summarise the clinical, animal and in vitro evidence evaluating the efficacy of DAP for the management of deep-seated VRE infections. In addition, we will address important clinical concerns such as the emergence of DAP resistance during therapy and reports of therapeutic failure with DAP monotherapy. Finally, we will discuss possible future strategies (such as the use of higher doses and/or combination therapies) to optimise the use of this antibiotic against VRE. es_CL
dc.format.extent 9 es_CL
dc.language.iso en_US es_CL
dc.publisher Elsevier es_CL
dc.subject Daptomycin es_CL
dc.subject VRE es_CL
dc.subject Enterococcal bacteraemia es_CL
dc.subject Enterococci es_CL
dc.title Daptomycin for the treatment of bacteraemia due to vancomycin-resistant enterococci es_CL
dc.type Artículo es_CL


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Browse

My Account